We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Launches New Solutions for Clinical Labs
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) introduced new sample preparation solutions to simplify and automate respiratory diagnostic testing. The company launched the Thermo Scientific KingFisher Apex Dx, an automated nucleic acid purification instrument and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit for the isolation and purification of viral and bacterial pathogens from respiratory biological specimens.
The recent development will further strengthen the company’s Life Science Solutions segment.
About Thermo Scientific KingFisher Apex Dx
Clinical laboratories that perform respiratory testing need to generate the highest quality results. To meet their needs, the high-throughput, versatile KingFisher Apex Dx system enables scientists’ labs to recover quality nucleic acids for sensitive downstream applications with maximum consistency, reproducibility, and reliability. The system is designed to be part of a modular sample preparation to real-time PCR analysis workflow, providing precise results, accurate data management and robust security features that meet cybersecurity and diagnostic regulatory standards.
Image Source: Zacks Investment Research
The KingFisher Apex Dx system automates the extraction of up to 24 or 96 DNA, RNA, protein, or cell samples and transitions from clinical research to diagnostics by offering research use only and IVD software modes. It can be integrated with a Laboratory Information Management System or Laboratory Information System via Diomni Enterprise Software for enhanced data management and workflow optimization.
About Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit
The MagMAX Dx Viral/Pathogen NA Isolation kit offers advanced formulation to ensure reproducible results and is automation-compatible with the KingFisher Apex Dx. The solution offers a new advanced formulation to maximize nucleic acid yield from routinely tested respiratory pathogens such as S. aureus, M. tuberculosis, influenza, RSV and SARS-CoV-2.
This kit also helps laboratories meet greener policies with REACH-compliant components and responsibly sourced packaging. Currently, the kit is available in in North America and coming soon to other regions.
More on the News
The KingFisher Apex Dx system builds on decades of product expertise and innovations, which have placed customers’ trust in the KingFisher instrument line. Per Thermo Fisher’s representative, the combination of the Apex Dx system and the MagMAX Dx Viral/Pathogen NA Isolation Kit further simplifies sample preparation for clinical labs so they can have confidence in downstream results when testing for respiratory diseases.
Together, these products provide laboratories with an in vitro diagnostic and in vitro diagnostic regulation approved automated sample preparation solutions for increased confidence in downstream results.
Industry Prospects
Per a Research report, the global life science tools market was valued at $144.1 billion in 2022 and is expected to witness a CAGR of 10.8% in the 2023-2030 period.
Recent Highlights in the Life Science Solutions Segment
Last month, Thermo Fisher and Flagship Pioneering expanded their ongoing strategic partnership to develop and commercially scale multi-product platforms on an accelerated basis. Together, the companies aim to create a new platform focused on novel tools and capabilities that seek to power the biotech ecosystem and accelerate the development of first-in-class therapies.
Price Performance
In the past six months, TMO shares have decreased 5.9% compared with the industry’s fall of 9.1%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Haemonetics’ stock has gained 4.1% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have remained unchanged at $1.91 in the past 30 days. Shares of the company have dropped 37.7% in the past year compared with the industry’s decline of 8.1%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.41 to $1.43 in the past 30 days and to $1.44 in the past seven days. Shares of the company have decreased 1.4% in the past year compared with the industry’s decline of 7.7%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Thermo Fisher (TMO) Launches New Solutions for Clinical Labs
Thermo Fisher Scientific (TMO - Free Report) introduced new sample preparation solutions to simplify and automate respiratory diagnostic testing. The company launched the Thermo Scientific KingFisher Apex Dx, an automated nucleic acid purification instrument and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit for the isolation and purification of viral and bacterial pathogens from respiratory biological specimens.
The recent development will further strengthen the company’s Life Science Solutions segment.
About Thermo Scientific KingFisher Apex Dx
Clinical laboratories that perform respiratory testing need to generate the highest quality results. To meet their needs, the high-throughput, versatile KingFisher Apex Dx system enables scientists’ labs to recover quality nucleic acids for sensitive downstream applications with maximum consistency, reproducibility, and reliability. The system is designed to be part of a modular sample preparation to real-time PCR analysis workflow, providing precise results, accurate data management and robust security features that meet cybersecurity and diagnostic regulatory standards.
Image Source: Zacks Investment Research
The KingFisher Apex Dx system automates the extraction of up to 24 or 96 DNA, RNA, protein, or cell samples and transitions from clinical research to diagnostics by offering research use only and IVD software modes. It can be integrated with a Laboratory Information Management System or Laboratory Information System via Diomni Enterprise Software for enhanced data management and workflow optimization.
About Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit
The MagMAX Dx Viral/Pathogen NA Isolation kit offers advanced formulation to ensure reproducible results and is automation-compatible with the KingFisher Apex Dx. The solution offers a new advanced formulation to maximize nucleic acid yield from routinely tested respiratory pathogens such as S. aureus, M. tuberculosis, influenza, RSV and SARS-CoV-2.
This kit also helps laboratories meet greener policies with REACH-compliant components and responsibly sourced packaging. Currently, the kit is available in in North America and coming soon to other regions.
More on the News
The KingFisher Apex Dx system builds on decades of product expertise and innovations, which have placed customers’ trust in the KingFisher instrument line. Per Thermo Fisher’s representative, the combination of the Apex Dx system and the MagMAX Dx Viral/Pathogen NA Isolation Kit further simplifies sample preparation for clinical labs so they can have confidence in downstream results when testing for respiratory diseases.
Together, these products provide laboratories with an in vitro diagnostic and in vitro diagnostic regulation approved automated sample preparation solutions for increased confidence in downstream results.
Industry Prospects
Per a Research report, the global life science tools market was valued at $144.1 billion in 2022 and is expected to witness a CAGR of 10.8% in the 2023-2030 period.
Recent Highlights in the Life Science Solutions Segment
Last month, Thermo Fisher and Flagship Pioneering expanded their ongoing strategic partnership to develop and commercially scale multi-product platforms on an accelerated basis. Together, the companies aim to create a new platform focused on novel tools and capabilities that seek to power the biotech ecosystem and accelerate the development of first-in-class therapies.
Price Performance
In the past six months, TMO shares have decreased 5.9% compared with the industry’s fall of 9.1%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Insulet (PODD - Free Report) and DexCom (DXCM - Free Report) . Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has gained 4.1% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have remained unchanged at $1.91 in the past 30 days. Shares of the company have dropped 37.7% in the past year compared with the industry’s decline of 8.1%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.41 to $1.43 in the past 30 days and to $1.44 in the past seven days. Shares of the company have decreased 1.4% in the past year compared with the industry’s decline of 7.7%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.